Optimizing therapy for Inflammatory Bowel Disease

American Journal of Gastroenterology

Volumn 92, Issue 12 SUPPL., 1997, Pages

  Robinson, Malcolm ^a  

^a Oklahoma Foundation for Digestive Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEMANNAN; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 11; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NICOTINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 0030853187     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334: 841-8.
2. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 1993;119:1198-208.
3. Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease: A review of their mechanisms of efficacy and place in therapy. Drugs 1989;38:267-88.
4. MacDermott RP. Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 1994;78:1207-31.
5. Margolin ML, Krumholz MP, Fochios SE, et al. Clinical trials in ulcerative colitis: II. Historical review. Am J Gastroenterol 1988;83: 227-43.
6. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991;6:192-219.
7. Salomon P, Kombluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992;14:211-5.
8. Kombluth AA, Salomon P, Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993;16:215-8.
9. Dahlberg E, Thalen A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity in some novel, highly active, 16α,17α-acetal-substituted glucocorticoids. Mol Pharmacol 1984;24:70-8.
10. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
11. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
12. Campieri M, Ferguson A, Doe W, and the International Budesonide Study Group. Oral budesonide competes favourably with prednisolone in active Crohn's disease. Gastroenterology 1995;108:A790.
13. Bayless T, Sninsky C, and the U.S. Budesonide Enema Study Group. Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis. Gastroenterology 1995;108:A778.
14. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide CIR for maintenance of remission in ileocecal Crohn's disease: A European multicenter placebo controlled trial for 12 months. Gastroenterology 1994;106:A722.
15. Miner P, Daly R, Nester T, and the Rowasa Study Group. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 1994;106:A736.
16. Habal FM, Kirkpatrick A, Greenberg GR. Long term safety of 5-aminosalicylic acid in inflammatory bowel disease: A seven year follow-up. Am J Gastroenterol 1994;89:1691 (abstract).
17. Nilsson Å, Danielsson Å, Löfberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: A multicenter study. Am J Gastroenterol 1995;90:381-7.
18. Abenhaim L, Sutherland LR, Field LG, et al. Has the introduction of a new mesalamine containing compound altered the clinical course of ulcerative colitis patients? Gastroenterology 1996;110:A850.
19. Hanauer SB, Barish C, Pambianco D, et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology 1996;110:A921.
20. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Gastroenterology 1995;108:A909.
21. Campieri M, Gionchetti P, Rizzello F, et al. A controlled randomized trial comparing oral versus rectal mesalazine in the treatment of ulcerative proctitis. Gastroenterology 1996;110:A876.
22. Mulder CJJ, Fockens P, van der Heide H, et al. A controlled randomized trial of beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (1 g) versus the combination of both (3 mg/l g) as retention enemas in active distal ulcerative colitis. Gastroenterology 1994;106:A739.
23. Farup PG, Hovde Ø, Halvorsen FA, et al. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis: A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 1995;30:164-70.
24. Candy S, Wright JP, Gerber M, et al. A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease. Gastroenterology 1994;106:A659.
25. Sandborn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109:1808-17.
26. Francella A, Dayan A, Rubin P, et al. 6-mercaptopurine (6-MP) is safe therapy for child bearing patients with inflammatory bowel disease (IBD): A case controlled study. Gastroenterology 1996;110:A909.
27. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
28. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
29. Cheetham BC, Harris MS. Efficacy and safety of subcutaneous (SQ) methotrexate in Crohn's disease: A preliminary report. Gastroenterology 1995;108:A796.
30. Sternthal M, George J, Kornbluth A, et al. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996;110:A1019.
31. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease: A meta-analysis. Ann Intern Med 1995;122: 132-42.
32. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 9:1711-4.
33. van Deventer SJH, Elson CO, Fedorak RN, and the IL-10 IBD Cooperative Study Group. Safety tolerance pharmacokinetics and pharmacodynamics of recombinant interleukin-10 (SCH 52000) in patients with steroid refractory Crohn's disease. Gastroenterology 1996;110: A1034.
34. Bank S, Sninsky C, Robinson M, et al. Safety and activity evaluation of rhIL-11 in subjects with active Crohn's disease. Gastroenterology 1997;112:A927.
35. Levine DS, Hanauer SB, Patt LM, et al., and the PCA Study Group. A placebo-controlled trial of prezatide copper acetate retention enemas in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 1997;112:A1026.
36. Stack W, Mann S, Roy A, et al. The effects of CDP571, an engineered human IgG4 anti-TNFα antibody, in Crohn's disease. Gastroenterology 1996;110:A1018.
37. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
38. Rutgeerts P, D'Haens G, van Deventer SJH, et al., and the Crohn's Disease cA2 Study Group. Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997;112:A1078.
39. Rubin PH, Chapman ML, Scherl E, et al. Clarithromycin in active Crohn's disease (CD): Preliminary results of open label pilot study. Gastroenterology 1996;110:A1005.
40. Greenbloom SL, Steinhart AH, Greenberg GR. Ciprofloxacin and metronidazole: Combination antibiotic therapy for ileocolonic Crohn's disease. Gastroenterology 1995;108:A827.
41. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
42. Robinson M, Reich C, Lashner B, et al. Evaluation of oral acemannan in active ulcerative colitis. Am J Gastroenterol 1994;89:1697 (abstract).
43. Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220-3.
44. Gaffney PR, Gaffney A. Heparin therapy in refractory ulcerative colitis: An update. Gastroenterology 1996;110:A913.
45. Brazier F, Yzet T, Duchmann JC, et al. Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel diseases. Gastroenterology 1996;110:A872.
46. Sandborn WJ, Tremaine W, Offord KP, et al. A randomized, double-blind, placebo-controlled trial of transdermal nicotine for mildly to moderately active ulcerative colitis. Gastroenterology 1996;110:A1008.
47. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S.